clinical trial · NCT04903314
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
SK Life Science, Inc.·phase1·completed·n = 26
Partial EpilepsyXcopri
brief summary
The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.
started
May 27, 2021
primary completion
Nov 6, 2025
completion
Nov 6, 2025
last updated
Mar 31, 2026
detailed description
The secondary objective of this study is to evaluate the safety and tolerability of cenobamate (YKP3089) following single and multiple dosing.
official title
A Phase I, Open-Label, Pharmacokinetic, Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol